{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:55:00Z","timestamp":1787532900223,"version":"build-2736575974"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.msard.2023.104692","type":"journal-article","created":{"date-parts":[[2023,3,31]],"date-time":"2023-03-31T15:44:08Z","timestamp":1680277448000},"page":"104692","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["The consequences of switching from Gilenya\u00ae to generics for fingolimod"],"prefix":"10.1016","volume":"74","author":[{"given":"Leslie","family":"Menendez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Osherov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeev","family":"Nitsan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marwan","family":"Alkrenawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Gelfand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nurit","family":"Hovel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shmuel","family":"Appel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8556-2579","authenticated-orcid":false,"given":"Ron","family":"Milo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2023.104692_bib0009","doi-asserted-by":"crossref","first-page":"639","DOI":"10.3111\/13696998.2013.778268","article-title":"The cost burden of multiple sclerosis in the United States: a systematic review of the literature","volume":"16","author":"Adelman","year":"2013","journal-title":"J. Med. Econ."},{"key":"10.1016\/j.msard.2023.104692_bib0015","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1212\/01.wnl.0000319958.37502.8e","article-title":"Generic substitution in the treatment of epilepsy","volume":"71","author":"Berg","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2023.104692_bib0012","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1038\/nrd3248","article-title":"Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis","volume":"9","author":"Brinkmann","year":"2010","journal-title":"Nat. Rev. Drug Discov"},{"key":"10.1016\/j.msard.2023.104692_bib0007","doi-asserted-by":"crossref","DOI":"10.1177\/1756286418774338","article-title":"Phase IV study of retention on fingolimod versus injectable multiple sclerosis therapies: a randomized clinical trial","volume":"11","author":"Cree","year":"2018","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.msard.2023.104692_bib0004","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1097\/WCO.0000000000000700","article-title":"Current therapeutic landscape in multiple sclerosis: an evolving treatment paradigm","volume":"32","author":"Cree","year":"2019","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.msard.2023.104692_bib0008","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s40263-018-0488-6","article-title":"Efficacy and safety of the newer multiple sclerosis drugs approved since 2010","volume":"32","author":"Fisasner","year":"2018","journal-title":"CNS Drugs"},{"key":"10.1016\/j.msard.2023.104692_bib0005","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.msard.2016.06.001","article-title":"Comparative efficacy of disease-modifying therapies for patients with relapsing remitting multiple sclerosis: systematic review and network meta-analysis","volume":"9","author":"Fogarty","year":"2016","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2023.104692_bib0010","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1212\/WNL.0000000000001608","article-title":"The cost of multiple sclerosis drugs in the US and the pharmaceutical industry: too big to fail?","volume":"84","author":"Hartung","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2023.104692_bib0018","unstructured":"Israel Ministry of Health, 2017a. Fingolimod-Teva Patient Leaflet. https:\/\/mohpublic.z6.web.core.windows.net\/IsraelDrugs\/Rishum01_1_1015022921.pdf (Accessed 12 April 2023)."},{"key":"10.1016\/j.msard.2023.104692_bib0019","unstructured":"Israel Ministry of Health, 2017b. Finolim Patient Leaflet. https:\/\/mohpublic.z6.web.core.windows.net\/IsraelDrugs\/Rishum_21_536872121.pdf (Accessed 12 April 2023)."},{"key":"10.1016\/j.msard.2023.104692_bib0013","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1056\/NEJMoa0909494","article-title":"A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis","volume":"362","author":"Kappos","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2023.104692_bib0020","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1111\/cts.12771","article-title":"Pharmacogenomics in Asian subpopulations and impacts on commonly prescribed medications","volume":"13","author":"Lo","year":"2020","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.msard.2023.104692_bib0006","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.msard.2018.12.040","article-title":"Systematic review and network meta-analysis comparing ocrelizumab with other treatments for relapsing multiple sclerosis","volume":"29","author":"McCool","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2023.104692_bib0014","doi-asserted-by":"crossref","first-page":"233","DOI":"10.2165\/00002018-199615040-00001","article-title":"Generic drugs. Therapeutic equivalence","volume":"15","author":"Meredith","year":"1996","journal-title":"Drug Saf."},{"key":"10.1016\/j.msard.2023.104692_bib0003","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1517\/14656566.2015.1002769","article-title":"Effectiveness of multiple sclerosis treatment with current immunomodulatory drugs","volume":"16","author":"Milo","year":"2015","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.msard.2023.104692_bib0002","unstructured":"Multiple Sclerosis International Federation, 2020. Atlas of MS, 3rd Ed. Part 1: Mapping multiple sclerosis around the world. https:\/\/www.msif.org\/wp-content\/uploads\/2020\/12\/Atlas-3rd-Edition-Epidemiology-report-EN-updated-30-9-20.pdf (Accessed 12 April 2023)."},{"key":"10.1016\/j.msard.2023.104692_bib0017","unstructured":"Novartis Pharmaceuticals Corporation, 2022. Gilenya prescribing Information. https:\/\/www.novartis.com\/us-en\/sites\/novartis_us\/files\/gilenya.pdf (Accessed 12 April 2023)."},{"key":"10.1016\/j.msard.2023.104692_bib0016","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s40263-021-00798-w","article-title":"Sphingosine 1phosphate receptor modulators for multiple sclerosis","volume":"35","author":"Roy","year":"2021","journal-title":"CNS Drugs"},{"key":"10.1016\/j.msard.2023.104692_bib0001","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1016\/S0140-6736(18)30481-1","article-title":"Multiple sclerosis","volume":"391","author":"Thompson","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.msard.2023.104692_bib0011","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1212\/WNL.0000000000002887","article-title":"Health insurance affects the use of disease modifying therapy in multiple sclerosis","volume":"87","author":"Wang","year":"2016","journal-title":"Neurology"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034823001967?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034823001967?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T09:05:20Z","timestamp":1761901520000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034823001967"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":20,"alternative-id":["S2211034823001967"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2023.104692","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The consequences of switching from Gilenya\u00ae to generics for fingolimod","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2023.104692","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104692"}}